GlobeNewswire by notified

Preliminary data on early redemptions (prepayments)


To Nasdaq Copenhagen A/S                                11 December 2023
                                        Announcement no. 113/2023

Preliminary data on early redemptions (prepayments)

Pursuant to S. 24 of the Capital Markets Act, we hereby publish preliminary data on early redemptions (prepayments) in bonds issued by Jyske Realkredit. Please find the data in the attached file.

The information will also be available on Jyske Realkredit’s web site at

For further information about format of data and content of the file we refer to the web site of Nasdaq at

Questions may be addressed to Christian Bech-Ravn, Head of Investor Relations, tel. (+45) 89 89 92 25.

Yours sincerely
Jyske Realkredit

Please observe that the Danish version of this announcement prevails


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

TCM Group A/S: Årsrapport 202328.2.2024 07:52:12 CET | pressemeddelelse

Selskabsmeddelelse Nr. 187/2024 Tvis, 28. februar 2024 Kvartalsrapport Q4 2023 (1. oktober – 31. december) (Tallene i parentes henviser til den tilsvarende periode i 2022 – AUBO Production A/S er inkl. i tallene pr. 3. juli 2023) Resultater for 4. kvartal bekræftet. CEO Torben Paulin: ”Som anført i vores selskabsmeddelelse nr. 185 dateret 18. januar 2024, udviklede køkkenmarkedet i Danmark sig mere positivt i 4. kvartal end tidligere forventet. Alle brands præsterede bedre end forventet, hvilket resulterede i at omsætningen oversteg vores tidligere forventninger. Omsætningen i 4. kvartal, hvilket inkluderede salg fra AUBO, var DKK 316 mio. sammenlignet med DKK 275 mio. i 4. kvartal sidste år, svarende til et organisk fald på 7,6% i kvartalet. I 4. kvartal blev bruttomarginen forbedret i forhold til 4. kvartal sidste år, drevet af et forbedret salgsmix, hvilket igen skyldes inklusionen af AUBO omsætningen og den fulde effekt af salgsprisstigningerne implementeret tidligere. Indtjeningen

TCM Group A/S: Annual report 202328.2.2024 07:52:12 CET | Press release

COMPANY ANNOUNCEMENT No. 187/2024 Tvis, 28 February 2024 Interim report Q4 2023 (October 1 - December 31) (All figures in brackets refer to the corresponding period in 2022 – AUBO Production A/S is the figures as from 3 July 2023) Q4 results confirmed. CEO Torben Paulin: “As stated in our Company Announcement no. 185 dated 18 January 2024, the kitchen market in Den-mark developed more positively in Q4 than previously expected. Performance was better across all brands, leading to sales exceeding our previous expectations. Revenue in Q4, which included sales from Aubo, was DKK 316 million compared to DKK 275 million in Q4 last year, corresponding to an organic decline of 7.6% in the quarter. In Q4 the gross margin improved on Q4 last year, driven by an improved sales mix, which in turn was due to the inclusion of AUBO sales and the full impact of the sales price increases implemented earlier. Earnings in Q4 were negatively affected by an increase in our provisions for potential l

Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning28.2.2024 07:32:56 CET | Press release

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released today an industry-leading report on Duchenne Muscular Dystrophy (DMD) Clinical Trial Landscape. The report includes emerging genetic therapies, funding landscape, and a SWOT analysis designed to inform strategic drug development decision-making and ultimately enhancing the chances of successful and impactful treatments for DMD. The Novotech research analyst team provides these expert reports monthly, completely free of charge. These reports offer current insights into global clinical trial activity, revealing which regions experience the highest trial volumes and the factors behind these trends. They tackle the hurdles faced by biotech firms in specific therapeutic areas and discuss future paths in therapy and investment trends. The Duch

BW Energy: Fourth Quarter and Full Year Results 202328.2.2024 07:30:00 CET | Press release

FOURTH QUARTER AND FULL YEAR RESULTS 2023 HIGHLIGHTS Q4 EBITDA of USD 133.4 million and net profit of USD 80.2 millionFull-year revenue of USD 0.5 billion (+83%) with EBITDA of USD 241.0 million (+56%) and net profit of USD 81.0 million (+80%)Q4 gross production of 3.03 million barrels with 2.48 million net to BW EnergyFour liftings of 2.7 million barrels (net BWE) at average realised price of USD ~82 per barrelAchieved combined production milestone of 50,000 operated barrels per day in OctoberMaintained a strong balance sheet with cash position of USD 194 millionCompleted acquisition of FPSO Cidade de VitóriaDiscovery of Hibiscus SouthMoU signed with Cosco Shipping Heavy Industry for FPSO BW Maromba upgrade BW Energy, operator of the Dussafu Marin licence in Gabon and the Golfinho cluster offshore Brazil, reported EBITDA for the fourth quarter of 2023 of USD 133.4 million, up from USD 49.7 million in the third quarter of 2023, due to increased production and liftings. Gross production

Ageas reports full-year results 202328.2.2024 07:30:00 CET | Press release

Ageasreportsfull-yearresults 2023 Excellent commercial performance in Non-Life across all segments and double-digit growth in Life in ChinaNet Operating Result at EUR 1,166 million, reflected by an excellent Operational Capital GenerationCash position increased significantly to EUR 959 millionProposed total dividend of EUR 3.25 per share, up more than 8%. Final dividend of EUR 1.75 per share KeyFigures (Group)ResultNet Operating Result of EUR 1,166 million, representing a 16.2 %Return on EquityNet Result of EUR953 millionOperational Capital Generation of EUR1,803 millionOperational Free Capital Generation of EUR 1,162 millionInflows (at constant exchange rate)Inflows grew 8% at constant exchange rates, amounting to EUR 17.1 billion driven by the excellent commercial performance in Non-Life and strong sales in Life in ChinaLife inflows stood at EUR 11.2 billion with lower inflows in Belgium and Europe, compensated by growth in AsiaNon-Life inflows grew 17 % at constant exchange rates an

HiddenA line styled icon from Orion Icon Library.Eye